and ADCK4, which regulate coenzyme Q 10 biosynthesis, may cause SRNS, and patients who carry these specific variants could benefit from coenzyme Q 10 supplementation. A high percentage of monogenic causation has also been detected in individuals manifesting with early-onset CKD due to other causes, such as cystic kidney diseases (>50%), urinary stone disease (21%), congenital anomalies of the kidneys and urinary tract (17%), and nephritis (15%). Overall, monogenic mutations in ~250 recessive or dominant genes are estimated to account for ~25% of all cases of early-onset (<25 years) CKD.
Cystic kidney diseases, also known as renal ciliopathies, are caused by a dysfunction of the primary cilia and centrosomes. Recent discoveries of mutations in the centrosomal protein CEP164 4 and FAN1 5 have implicated DNA damage response signalling in the pathogenesis of renal ciliopathies.
This finding led to the proposal that accumulation of DNA damage with consecutive premature cellular senescence could contribute markedly to the development of renal fibrosis, which is central to all forms of CKD independent of the primary cause. Loss-offunction mutations in recessive monogenic kidney disease genes can be readily modelled and characterized in animals, such as mice or zebrafish, by knockdown and/or knockout approaches. The first successful treatment approaches for renal cilio pathies were demonstrated in mouse models, as exemplified in a study that addressed impaired cell cycle dysregulation as a potential cause of cysto genesis. Administration of a cyclin-dependent kinase inhibitor, roscovitine, in mouse models of juvenile and congenital poly cystic kidney disease efficiently arrested cystic disease. The mechanism of action revealed effective cell-cycle arrest, transcriptional inhibition, and attenuation of apoptosis. 6 Studies performed over the past decade have also focused on determining the contribution of single gene causes of adultonset CKD. Researchers found that the NPHS2 (podocin) gene variant R229Q, which had been considered a variant of unknown significance for many years, is in fact disease-causing when expressed in a compound heterozygous state with one of a few other distinct NPHS2 mutations. 7 The combination of heterozygous mutations on both NPHS2 alleles was shown to result in adult onset of SRNS. 'Mild' recessive genetic variants are most likely to cause late-onset forms of disease and, therefore, might explain a considerable proportion of adult-onset CKD.
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NEWS & VIEWS
Whereas monogenic mutations are usually discovered by whole exome sequencing, variants that underlie polygenic disorders are usually detected by genomewide association studies (GWAS). Polygenic disorders are more common than are monogenic disorders, exert weak caus ality (or risk) on the disease phenotype, usually manifest later in life, and are often modified by environmental effects. Risk alleles usually account for only a small proportion of the variance of the disease phenotype, and the mechanistic assignment of an associ ated marker allele to loss of gene function is difficult to ascertain.
An important discovery attained by GWAS was the detection of a single nucleotide polymorphism, rs12917707, located near the UMOD gene, which if mutated, causes autosomal dominant medullary cystic kidney disease type 2. 8 This finding was later confirmed in a large worldwide cohort. Another breakthrough GWAS study, published at the turn of the decade, reported an association between APOL1 variants and CKD. Two variants were found to be strongly associated with an increased risk of focal segmental glomerulosclerosis (FSGS) and CKD in African Americans. 9 More than half of African Americans in the USA (compared with 4% of European Americans) carry both recessive APOL1 risk alleles, increasing the risk of developing FSGS by 5-30 fold. These data likely explain the known racial disparities in non-diabetic nephropathy seen in African Americans. 10 The two APOL1 risk alleles always occur on different homologous chromosomes and thereby behave like recessive mutations.
As this article has exemplified, technological approaches to probe and dissect the human genome have rapidly progressed over the past 10 years, and the cost of performing such investigations has decreased. The ability to perform GWAS in large, worldwide cohorts of patients with complex, polygenic kidney disorders is enabling researchers to identify new risk alleles for investigation and to help determine disease causality and prevalence in various populations. In the near future we may be able to perform functional studies of the many genetic variants of recessive and dominant causative genes for CKD, for which there is currently not enough evidence to indicate a deleterious effect. Genetic manipulation techniques have also advanced, enabling scientists to readily and accurately model gene variants and mutations in vitro and in vivo to ascertain gene function. The identification of single-gene mutations in patients with kidney disorders, by methods such as whole exome sequen cing, has revolutionized our practice of diagnosing and understanding disease pathogenesis. Continued discovery of novel disease-causing genes will enable the provision of an unequivocal molecular genetic diagnosis to patients, generate new insights into disease mechanisms, and have consequences for personalized treatment and prevention of CKD in the future. The functional characterization of deleterious variants in known kidney disease genes will be one of the most important and rewarding contributions to understanding renal pathogenesis in the coming decade.
